Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies

British Journal of Cancer

Volumn 93, Issue 5, 2005, Pages 529-537

  Geoerger, B ^a   Vassal, G ^a   Doz, F ^b   O'Quigley, J ^b   Wartelle, M ^a   Watson, A J ^c   Raquin, M A ^a   Frappaz, D ^d   Chastagner, P ^e   Gentet, J C ^f   Rubie, H ^g   Couanet, D ^a   Geoffray, A ^h   Djafari, L ⁱ   Margison, G P ^c   Pein, F ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT CURIE   (France)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d CENTRE LÉON BÉRARD   (France)

^e HÔPITAL D ENFANTS   (France)

^f TIMONE HOSPITAL   (France)

^g CHU PURPAN   (France)

^h Fondation Lenval Hopital pour Enfants   (France)

ⁱ Schering Plough   (France)

Author keywords

Cisplatin; CRM; MGMT; Paediatric phase I II; Temozolomide

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; CISPLATIN; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE; DRUG DERIVATIVE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ADOLESCENT; ADULT; ALERTNESS; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE MARROW; BRAIN STEM; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEHYDRATION; DISEASE SEVERITY; DNA REPAIR; DOSE RESPONSE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GLIOMA; HALLUCINATION; HEADACHE; HEARING LOSS; HUMAN; HYPOACUSIS; INFANT; INFECTION; INTRACRANIAL HYPERTENSION; IRRADIATION; MALE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROBLASTOMA; NEUTROPENIA; OTOTOXICITY; PEDIATRICS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPTICEMIA; SOLID TUMOR; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VOMITING; CANCER STAGING; DRUG RESISTANCE; ENZYMOLOGY; MAXIMUM TOLERATED DOSE; METABOLISM; NEOPLASM; PRESCHOOL CHILD; SALVAGE THERAPY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CISPLATIN; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFANT; MALE; MAXIMUM TOLERATED DOSE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 26944491168     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602740     Document Type: Article

References (43)

1. Bleehen NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH, Rustin GJ, Brampton M, Stevens MF (1995) Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 13: 910-913
2. Bocangel DB, Finkelstein S, Schold SC, Bhakat KK, Mitra S, Kokkinakis DM (2002) Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res 8: 2725-2734
3. Brandes AA, Basso U, Reni M, Vastola F, Tosoni A, Cavallo G, Scopece L, Ferreri AJ, Panucci MG, Monfardini S, Ermani M (2004) First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase ii study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. J Clin Oncol 22: 1598-1604
4. Britten CD, Rowinsky EK, Baker SD, Agarwala SS, Eckardt JR, Barrington R, Diab SG, Hammond LA, Johnson T, Villalona-Calero M, Fraass U, Statkevich P, Von Hoff DD, Eckhardt SG (1999) A phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clin Cancer Res 5: 1629-1637
5. D'Atri S, Graziani G, Lacal PM, Nistico V, Gilberti S, Faraoni I, Watson AJ, Bonmassar E, Margison GP (2000) Attenuation of O(6)-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells. J Pharmacol Exp Ther 294: 664-671
6. D'Atri S, Piccioni D, Castellano A, Tuorto V, Franchi A, Lu K, Christiansen N, Frankel S, Rustum YM, Papa G (1995) Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukaemic patients. Ann Oncol 6: 389-393
7. Dolan ME, Chae MY, Pegg AE, Mullen JH, Friedman HS, Moschel RC (1994) Metabolism of O6-benzylguanine, an inactivator of O6-alkylguanine-DNA alkyltransferase. Cancer Res 54: 5123-5130
8. Dolan ME, Stine L, Mitchell RB, Moschel RC, Pegg AE (1990) Modulation of mammalian O6-alkylguanine-DNA alkyltransferase in vivo by O6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4- methylcyclohexyl)-1-nitrosourea. Cancer Commun 2: 371-377
9. Estlin EJ, Lashford L, Ablett S, Price L, Gowing R, Gholkar A, Kohler J, Lewis IJ, Morland B, Pinkerton CR, Stevens MC, Mott M, Stevens R, Newell DR, Walker D, Dicks-Mireaux C, McDowell H, Reidenberg P, Statkevich P, Marco A, Batra V, Dugan M, Pearson AD (1998) Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group. Br J Cancer 78: 652-661
10. Fishel ML, Delaney SM, Friesen LD, Hansen RJ, Zuhowski EG, Moschel RC, Egorin MJ, Dolan ME (2003) Enhancement of platinum-induced cytotoxicity by O6-benzylguanine. Mol Cancer Ther 2: 633-640
11. Gander M, Leyvraz S, Decosterd L, Bonfanti M, Marzolini C, Shen F, Lienard D, Perey L, Colella G, Biollaz J, Lejeune F, Yarosh D, Belanich M, D'Incalci M (1999) Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. Ann Oncol 10: 831-838
12. Gerson SL (2002) Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20: 2388-2399
13. Hirose Y, Berger MS, Pieper RO (2001) p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 61: 1957-1963
14. Karran P, Hampson R (1996) Genomic instability and tolerance to alkylating agents. Cancer Surv 28: 69-85
15. Korn EL, Midthune D, Chen TT, Rubinstein LV, Christian MC, Simon RM (1999) Commentary. Stat Med 18: 2691-2692
16. Lashford LS, Thiesse P, Jouvet A, Jaspan T, Couanet D, Griffiths PD, Doz F, Ironside J, Robson K, Hobson R, Dugan M, Pearson AD, Vassal G, Frappaz D (2002) Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol 20: 4684-4691
17. Lee SM, Thatcher N, Crowther D, Margison GP (1994) Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer 69: 452-456
18. Liu L, Markowitz S, Gerson SL (1996) Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res 56: 5375-5379
19. Middlemas DS, Stewart CF, Kirstein MN, Poquette C, Friedman HS, Houghton PJ, Brent TP (2000) Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res 6: 998-1007
20. Middleton MR, Kelly J, Thatcher N, Donnelly DJ, McElhinney RS, McMurry TB, McCormick JE, Margison GP (2000a) O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts. Int J Cancer 85: 248-252
21. Middleton MR, Lee SM, Arance A, Wood M, Thatcher N, Margison GP (2000b) O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study. Int J Cancer 88: 469-473
22. Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS, Quarterman CP, Hoffman R, Stevens MF, Brampton MH (1992) Phase I trial of temozolomide. Br J Cancer 65: 287-291
23. Nicholson HS, Krailo M, Ames MM, Seibel NL, Reid JM, Liu-Mares W, Vezina LG, Ettinger AG, Reaman GH (1998) Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children's Cancer Group. J Clin Oncol 16: 3037-3043
24. O'Dwyer PJ, Johnson SW, Hamilton TC (1997) Cisplatin and its analogues. In Cancer: Principles and Practice of Oncology DeVita VTJ, Hellman S, Rosenberg SA (eds). pp 418-432. New York: Lippincott-Raven Publishers
25. O'Quigley J (1999) Another look at two phase I clinical trial designs. Stat Med 18: 2683-2690
26. O'Quigley J, Paoletti X (2003) Continual reassessment method for ordered groups. Biometrics 59: 430-440
27. O'Quigley J, Reiner E. (1998) A stopping rule for the continual reassessment method. Biometrika 85: 741-748
28. O'Quigley J, Shen LZ, Gamst A (1999) Two-sample continual reassessment method. J Biopharm Stat 9: 17-44
29. O'Reilly SM, Newlands ES, Glaser MG, Brampton M, Rice-Edwards JM, Illingworth RD, Richards PG, Kennard C, Colquhoun IR, Lewis P (1993) Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 29A: 940-942
30. Patel M, McCully C, Godwin K, Balis FM (2003) Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol 61: 203-207
31. Pegg AE (2000) Repair of O(6)-alkylguanine by alkyltransferases. Mutat Res 462: 83-100
32. Piccioni D, D'Atri S, Papa G, Caravita T, Franchi A, Bonmassar E, Graziani G (1995) Cisplatin increases sensitivity of human leukemic blasts to triazene compounds. J Chemother 7: 224-229
33. Plowman J, Waud WR, Koutsoukos AD, Rubinstein LV, Moore TD, Grever MR (1994) Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1- nitrosourea. Cancer Res 54: 3793-3799
34. Preuss I, Thust R, Kaina B (1996) Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs. Int J Cancer 65: 506-512
35. Silvani A, Eoli M, Salmaggi A, Lamperti E, Maccagnano E, Broggi G, Boiardi A (2003) Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients. J Neurooncol 66: 203-208
36. Smith M, Bernstein M, Bleyer WA, Borsi JD, Ho P, Lewis IJ, Pearson A, Pein F, Pratt C, Reaman G, Riccardi R, Seibel N, Trueworthy R, Ungerleider R, Vassal G, Vietti T (1998) Conduct of phase I trials in children with cancer. J Clin Oncol 16: 966-978
37. Tentori L, Graziani G (2002) Pharmacological strategies to increase the antitumor activity of methylating agents. Curr Med Chem 9: 1285-1301
38. Tentori L, Lacal PM, Benincasa E, Franco D, Faraoni I, Bonmassar E, Graziani G (1998) Role of wild-type p53 on the antineoplastic activity of temozolomide alone or combined with inhibitors of poly(ADP-ribose) polymerase. J Pharmacol Exp Ther 285: 884-893
39. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
40. Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A, Goetz AD, Schwartz G, Edwards T, Reyderman L, Statkevich P, Cutler DL, Rowinsky EK (2003) Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88: 1004-1011
41. Wang LG, Setlow RB (1989) Inactivation of O6-alkylguanine-DNA alkyltransferase in HeLa cells by cisplatin. Carcinogenesis 10: 1681-1684
42. Watson AJ, Margison GP (2000) O6-alkylguanine-DNA alkyltransferase assay. Methods Mol Biol 152: 49-61
43. Wedge SR, Porteus JK, May BL, Newlands ES (1996) Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro. Br J Cancer 73: 482-490